BeiGene
BGNE
#963
Rank
C$28.77 B
Marketcap
$253.60
Share price
1.02%
Change (1 day)
7.80%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of September 2024 : C$8.37 Billion

According to BeiGene 's latest financial reports the company's total assets are C$8.37 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31C$7.69 B-11.05%
2022-12-31C$8.65 B-20.42%
2021-12-31C$10.87 B52.32%
2020-12-31C$7.14 B239.14%
2019-12-31C$2.10 B-31.29%
2018-12-31C$3.06 B132.92%
2017-12-31C$1.31 B141.25%
2016-12-31C$0.54 B236.69%
2015-12-31C$0.16 B160.3%
2014-12-31C$62.22 M395.47%
2013-12-31C$12.55 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
C$26.1 M-99.69%๐Ÿ‡บ๐Ÿ‡ธ USA
C$3.24 B-61.31%๐Ÿ‡บ๐Ÿ‡ธ USA